JP2005194239A - Ceramide synthesis promotor and skin care preparation for external use - Google Patents
Ceramide synthesis promotor and skin care preparation for external use Download PDFInfo
- Publication number
- JP2005194239A JP2005194239A JP2004003287A JP2004003287A JP2005194239A JP 2005194239 A JP2005194239 A JP 2005194239A JP 2004003287 A JP2004003287 A JP 2004003287A JP 2004003287 A JP2004003287 A JP 2004003287A JP 2005194239 A JP2005194239 A JP 2005194239A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- asana
- ceramide synthesis
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940106189 ceramide Drugs 0.000 title claims abstract description 31
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 30
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 30
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 30
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 22
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 58
- 230000000694 effects Effects 0.000 claims abstract description 22
- NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 claims description 32
- 206010013786 Dry skin Diseases 0.000 claims description 16
- 230000037336 dry skin Effects 0.000 claims description 15
- 241000244268 Peucedanum japonicum Species 0.000 abstract description 3
- 235000009984 Pterocarpus indicus Nutrition 0.000 abstract description 3
- 241001571446 Scaphium scaphigerum Species 0.000 abstract description 3
- 241000446537 Symplocos racemosa Species 0.000 abstract description 3
- 241001446503 Pterocarpus Species 0.000 abstract 2
- 206010040849 Skin fissures Diseases 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 47
- 238000004519 manufacturing process Methods 0.000 description 41
- 238000009472 formulation Methods 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 229940058015 1,3-butylene glycol Drugs 0.000 description 24
- 235000019437 butane-1,3-diol Nutrition 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 23
- 239000008213 purified water Substances 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000006071 cream Substances 0.000 description 12
- 239000000469 ethanolic extract Substances 0.000 description 11
- -1 sorbit Chemical compound 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000006286 aqueous extract Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241001412225 Firmiana simplex Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、アサナ、ロッダ、ハンタイカイ及びサクナの抽出物から選ばれる1種又は2種以上を含有することを特徴とするセラミド合成促進剤に関し、特に肌荒れ、乾燥肌の防止に有効性を発揮するセラミド合成促進剤に関するものである。 The present invention relates to a ceramide synthesis promoter characterized by containing one or more selected from extracts of asana, rodda, hantaikai, and sacuna, and is particularly effective in preventing rough skin and dry skin. The present invention relates to a ceramide synthesis accelerator.
セラミドは、皮膚の基底層から角質層に細胞が移行する際に、上層の有棘層及び顆粒層で産生、分泌される層板顆粒の主成分であり、皮膚のバリア機能や水分保持能に重要な役割を果たす角質細胞間脂質を形成する。肌荒れの一因として乾燥や刺激物との接触や紫外線等による皮膚の炎症がある。乾燥や刺激物から肌を守るバリア機能の回復において、セラミドの産生を促進することが有効であるとされている。ヒト皮膚には、7系統のセラミドが存在することが確認されており、全種類のセラミドが角質層に存在する比率で補うことが理想的である。 Ceramide is the main component of lamellar granules produced and secreted in the upper spiny layer and granule layer when cells move from the basal layer of the skin to the stratum corneum. Forms keratinocyte lipids that play an important role. Causes of rough skin include dryness, contact with irritants, and skin irritation due to ultraviolet rays. It is said that promoting the production of ceramide is effective in restoring the barrier function that protects the skin from dryness and irritants. It has been confirmed that seven types of ceramide are present in human skin, and it is ideal that all kinds of ceramides are supplemented at a ratio of existing in the stratum corneum.
従来、この様な肌荒れ、乾燥肌の予防改善に有効な化粧料として、セラミドが種々の皮膚外用剤に配合されているが、ヒトの皮膚に存在する全種類のセラミドを適正な比率で補充することは技術的に困難であった。生体内におけるセラミド合成を促進するセラミド合成促進剤として、特許文献1や特許文献2が報告されているが、効果が十分とはいい難かった。なお、アサナ、ロッダ、ハンタイカイ及びサクナの抽出物のセラミド合成促進効果については報告されていない。
以上のことから、肌荒れ、乾燥肌の改善効果に優れたセラミド合成促進剤及び皮膚外用剤が望まれている。 From the above, a ceramide synthesis accelerator and a skin external preparation excellent in the effect of improving rough skin and dry skin are desired.
この様な事情により、本発明者らは鋭意研究検討した結果、アサナ、ロッダ、ハンタイカイ及びサクナの抽出物によりセラミド合成が促進されることを見出し、さらにそれらの抽出物から選ばれる1種又は2種以上に肌荒れ、乾燥肌の予防改善効果を見出し、本発明を完成するに至った。 Under these circumstances, as a result of intensive studies, the present inventors have found that ceramide synthesis is promoted by extracts of asana, rodda, hantaikai, and sacuna, and further, one or two selected from these extracts As a result, the present inventors have completed the present invention by finding an effect of preventing and improving rough skin more than seeds and dry skin.
本発明に用いるアサナは、マメ科に属し、学名:Pterocarpus marsapiumであり、その種子が抗炎症、止血、皮膚病、打撲に用いられてきた。ロッダはハイノキ科に属し、学名:Symplocos racemosa でありアメリカ原産の植物である。ハンタイカイはアオギリ科に属する落葉高木で学名:Sterculia scaphigera Wall である。また、サクナはセリ科に属する常緑の多年草であり、学名はPeucedanum japonicum であり、その根の部分が疲労回復、滋養強壮に用いられてきた。 Asana used in the present invention belongs to the leguminous family and has the scientific name: Pterocarpus marsapium, and its seed has been used for anti-inflammation, hemostasis, skin diseases and bruises. Rodda belongs to the cypress family and has the scientific name: Symplocos racemosa and is a plant native to the United States. Hanta Taikai is a deciduous tree belonging to the family Aogiri and has the scientific name: Sterculia scaphigera Wall. Sacna is an evergreen perennial plant belonging to the celery family, and its scientific name is Peucedanum japonicum, and its root has been used for recovery from fatigue and nourishment.
本発明のアサナ、ロッダ、ハンタイカイ及びサクナの抽出方法は特に限定されず、例えば、加熱抽出したものであっても良いし、常温又は低温で抽出したものであっても良い。抽出する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、1,3−ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は1種でも2種以上を混合して用いても良い。 The extraction method of asana, rodda, hantaikai, and sacuna of the present invention is not particularly limited. For example, it may be extracted by heating, or may be extracted at room temperature or low temperature. Examples of the solvent to be extracted include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol). , Glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether) Etc.). Preferred are polar solvents such as water, lower alcohols and liquid polyhydric alcohols, and particularly preferred are water, ethanol, 1,3-butylene glycol and propylene glycol. These solvents may be used alone or in combination of two or more.
上記抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、希釈、濾過、活性炭等による脱色、脱臭等の処理をして用いても良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良いし、カラム精製等を行って有効成分を濃縮したり単離してから用いても良い。 The above extract may be used as it is, or may be used after treatment such as concentration, dilution, filtration, decolorization with activated carbon, deodorization, etc., if necessary. Further, the extracted solution may be used as a dried product after being concentrated and dried, spray dried, freeze dried, etc., or may be used after concentrating or isolating the active ingredient by performing column purification or the like. good.
本発明のアサナ、ロッダ、ハンタイカイ及びサクナの抽出物から選ばれる1種又は2種以上を含有することを特徴とするセラミド合成促進剤を肌荒れ改善の目的で用いるには、通常全身的又は局所的に内用や外用により投与される。投与量は、年齢、体重、症状、治療効果、投与方法、処理時間などにより異なるが、通常成人1人当たり1回に1mg〜1g、好ましくは20mg〜200mgの範囲で1日1回から数回投与される。投与量は種々の条件で変動するので、上記投与範囲より少ない量で十分な場合もあるし、また、範囲を超えて投与する必要のある場合もある。 In order to use the ceramide synthesis promoter characterized in that it contains one or more selected from the extracts of asana, rodda, hantaikai and sacuna of the present invention for the purpose of improving rough skin, it is usually systemic or topical. It is administered by internal or external use. The dose varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually 1 mg to 1 g per adult, preferably 20 mg to 200 mg once to several times a day. Is done. Since the dosage varies depending on various conditions, an amount smaller than the above-mentioned administration range may be sufficient, or it may be necessary to administer beyond the range.
本発明の経口投与のためのセラミド合成促進剤としては、錠剤、丸剤、散剤、顆粒剤、カプセル剤、乳濁剤、溶液剤、懸濁剤、シロップ剤、エリキシル剤などが挙げられる。上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、賦形剤、増量剤、結合剤、湿潤剤、崩壊剤、表面活性剤、滑沢剤、分散剤、緩衝剤、香料、保存料、溶解補助剤、溶剤等を用いることができる。具体的には、乳糖、ショ糖、ソルビット、マンニット、澱粉、沈降性炭酸カルシウム、重質酸化マグネシウム、タルク、ステアリン酸カルシウム、ステアリン酸マグネシウム、セルロース又はその誘導体、アミロペクチン、ポリビニルアルコール、ゼラチン、界面活性剤、水、生理食塩水、エタノール、グリセリン、プロピレングリコール、カカオ脂、ラウリン脂、ワセリン、パラフィン、高級アルコール等である。 Examples of the ceramide synthesis promoter for oral administration of the present invention include tablets, pills, powders, granules, capsules, emulsions, solutions, suspensions, syrups, and elixirs. The above extract may be used as it is, and the excipient, extender, binder, wetting agent, disintegrant, surfactant, lubricant, dispersant, buffer, as long as the effect of the extract is not impaired. Agents, fragrances, preservatives, solubilizers, solvents and the like can be used. Specifically, lactose, sucrose, sorbit, mannitol, starch, precipitated calcium carbonate, heavy magnesium oxide, talc, calcium stearate, magnesium stearate, cellulose or derivatives thereof, amylopectin, polyvinyl alcohol, gelatin, surface activity Agent, water, physiological saline, ethanol, glycerin, propylene glycol, cacao butter, laurin butter, petrolatum, paraffin, higher alcohol and the like.
本発明の皮膚外用剤は、化粧品、医薬部外品及び医薬品のいずれにも用いることができ、その剤形としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤等の皮膚に適用されるものが挙げられる。上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤等の成分を配合することもできる。 The skin external preparation of the present invention can be used for any of cosmetics, quasi drugs, and pharmaceuticals. Examples of the dosage form include skin lotions, creams, emulsions, gels, aerosols, essences, packs, Examples of the cleaning agent, bath preparation, foundation, dusting powder, lipstick, ointment, and poultice applied to the skin. The above-mentioned extract may be used as it is, and the components used for the external preparation are within the range not impairing the effect of the extract, oils, waxes, hydrocarbons, fatty acids, alcohols, esters, interfaces Components such as activators, metal soaps, pH adjusters, preservatives, fragrances, moisturizers, powders, ultraviolet absorbers, thickeners, dyes, antioxidants, whitening agents, chelating agents, and the like can also be blended.
本発明に用いる上記抽出物の配合量は、本発明のセラミド合成促進剤に対し、固形物に換算して0.0001重量%以上、好ましくは0.001〜50重量%の配合が良い。0.0001重量%未満では十分な効果は望みにくい。50重量%を越えて配合した場合、効果の増強はみられにくく不経済である。また、添加の方法については、予め加えておいても、製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。 The amount of the extract used in the present invention is 0.0001% by weight or more, preferably 0.001 to 50% by weight, in terms of solid matter, based on the ceramide synthesis accelerator of the present invention. If it is less than 0.0001% by weight, a sufficient effect is hardly expected. When it exceeds 50% by weight, the effect is hardly increased and it is uneconomical. In addition, the addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.
本発明のアサナ、ロッダ、ハンタイカイ及びサクナの抽出物はセラミド合成促進効果に優れていた。また、これらの抽出物を含有する皮膚外用剤は、安全で肌荒れ、乾燥肌の改善効果に優れていた。 The extract of asana, rodda, hantaikai and sacuna of the present invention was excellent in ceramide synthesis promoting effect. Moreover, the skin external preparation containing these extracts was safe and rough, and was excellent in the improvement effect of dry skin.
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、本発明の処方例及び実験例を挙げるが、本発明はこれに限定されるものではない。実施例に示す配合量の部とは重量部を示し、%は重量%を示す。 Next, in order to describe the present invention in detail, examples of producing the extract used in the present invention, formulation examples and experimental examples of the present invention will be given as examples, but the present invention is not limited thereto. The part of the amount shown in the examples indicates part by weight, and% indicates% by weight.
製造例1 アサナの熱水抽出物
アサナの樹皮の乾燥物100gに精製水2Lを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してアサナの熱水抽出物を2.6g得た。
Production Example 1 Hot water extract of asana Add 2 L of purified water to 100 g of dried asana bark, extract at 95-100 ° C. for 2 hours, filter, concentrate the filtrate, freeze-dry and heat asana. 2.6 g of water extract was obtained.
製造例2 アサナのエタノール抽出物
アサナの樹皮及び茎の乾燥物100gにエタノール2Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、アサナのエタノール抽出物を4.5g得た。
Production Example 2 Asana ethanol extract 100 g of dried asana bark and stems were added with 2 L of ethanol, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain 4 ethanol extracts of asana. .5 g was obtained.
製造例3 アサナの50%1,3−ブチレングリコール水溶液抽出物
アサナの種子及び樹皮の乾燥物20gに精製水200mL及び1,3−ブチレングリコール200mLを加え、常温で7日間抽出した後、濾過し、アサナの50%1,3−ブチレングリコール抽出物を360g得た。
Production Example 3 Asana 50% 1,3-butylene glycol aqueous extract Asana seeds and bark dried 20 g were added with 200 mL of purified water and 200 mL of 1,3-butylene glycol, extracted at room temperature for 7 days, and then filtered. , 360 g of asana 50% 1,3-butylene glycol extract was obtained.
製造例4 ロッダの熱水抽出物
ロッダの葉及び果実の乾燥物20gに精製水400mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してロッダの熱水抽出物を3.0g得た。
Production Example 4 Hot Water Extract of Rodda 400 ml of purified water was added to 20 g of dried Rhoda leaves and fruits, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated, freeze-dried and Rhoda 3.0 g of a hot water extract was obtained.
製造例5 ロッダのエタノール抽出物
ロッダの樹皮の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固してロッダのエタノール抽出物を5.8g得た。
Production Example 5 Rhoda ethanol extract 100 g dry roda bark was added with 1 L of ethanol, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain 5.8 g of Rhoda ethanol extract. It was.
製造例6 ロッダの50%1,3−ブチレングリコール水溶液抽出物
ロッダの葉及び樹皮の乾燥物20gに精製水200mL及び1,3−ブチレングリコール200mLを加え、常温で7日間抽出した後、濾過し、ロッダの50%1,3−ブチレングリコール抽出物を380g得た。
Production Example 6 50% 1,3 Butylene Glycol Aqueous Extract of Rodda 200 ml of purified water and 200 ml of 1,3-butylene glycol were added to 20 g of dried Rodda leaves and bark, extracted for 7 days at room temperature, and then filtered. 380 g of 50% 1,3-butylene glycol extract of Rodda was obtained.
製造例7 ハンタイカイの熱水抽出物
ハンタイカイの種子の乾燥物20gに精製水800mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してハンタイカイの熱水抽出物を3.4g得た。
Production Example 7 Hot water extract of hantai kai 800 ml of purified water was added to 20 g of dried hantai kai seeds, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and freeze-dried. 3.4 g of water extract was obtained.
製造例8 ハンタイカイのエタノール抽出物
ハンタイカイの種子及び根の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固し、ロッダのエタノール抽出物を6.7g得た。
Production Example 8 Hantaikai Ethanol Extract 100 g of dried huntaikai seeds and roots was added with 1 L of ethanol, extracted at room temperature for 7 days, filtered, the filtrate was concentrated to dryness, and the Rhoda ethanol extract was obtained. 7 g was obtained.
製造例9 ハンタイカイの50%1,3−ブチレングリコール水溶液抽出物
ハンタイカイの葉及び種子の乾燥物20gに精製水200mL及び1,3−ブチレングリコール200mLを加え、常温で7日間抽出した後、濾過し、ロッダの50%1,3−ブチレングリコール抽出物を370g得た。
Manufacture example 9 50% 1,3-butylene glycol aqueous extract of hantai kai 200 ml of purified water and 200 ml of 1,3-butylene glycol were added to 20 g of dried hantai kai leaves and seeds, extracted at room temperature for 7 days, and then filtered. 370 g of a 50% 1,3-butylene glycol extract of Rodda was obtained.
製造例10 サクナの熱水抽出物
サクナの枝及び根の乾燥物50gに精製水1Lを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してサクナの熱水抽出物を12g得た。
Production Example 10 Sacuna hot water extract 1 L of purified water was added to 50 g of dried sakuna branches and roots, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated, freeze-dried, and dried. 12 g of a hot water extract was obtained.
製造例11 サクナのエタノール抽出物
サクナの葉及び枝の乾燥物50gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固し、サクナのエタノール抽出物を9.8g得た。
Production Example 11 Sacuna Ethanol Extract 50 g of dried sakuna leaves and branches was added with 1 L of ethanol, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness. 8 g was obtained.
製造例12 サクナの50%1,3−ブチレングリコール水溶液抽出物
サクナの枝の乾燥物20gに精製水200mL及び1,3−ブチレングリコール200mLを加え、常温で7日間抽出した後、濾過し、ロッダの50%1,3−ブチレングリコール抽出物を350g得た。
Production Example 12 Extract of 50% 1,3-butylene glycol aqueous solution of sacuna 200 mL of purified water and 200 mL of 1,3-butylene glycol were added to 20 g of a dried product of sacna branches, extracted at room temperature for 7 days, filtered, and filtered. 350 g of 50% 1,3-butylene glycol extract was obtained.
処方例1 クリーム1
処方 配合量
1.アサナの熱水抽出物(製造例1) 1.0部
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.1,3−ブチレングリコール 8.5
12.パラオキシ安息香酸エチル 0.05
13.パラオキシ安息香酸メチル 0.2
14.精製水 67.15
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
Formulation Example 1 Cream 1
Formulation Formulation 1. 1. Asana hot water extract (Production Example 1) 1.0 part Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5). Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11.1,3-butylene glycol 8.5
12 Ethyl paraoxybenzoate 0.05
13. Methyl paraoxybenzoate 0.2
14 Purified water 67.15
[Manufacturing method] Components 2 to 9 are heated and dissolved and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 11 to 14 are heated and dissolved and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
処方例2 クリーム2
処方 配合量
1.ロッダの熱水抽出物(製造例4) 1.0部
2.ハンタイカイの熱水抽出物(製造例7) 1.0
3.スクワラン 5.5
4.オリーブ油 3.0
5.ステアリン酸 2.0
6.ミツロウ 2.0
7.ミリスチン酸オクチルドデシル 3.5
8.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
9.ベヘニルアルコール 1.5
10.モノステアリン酸グリセリン 2.5
11.香料 0.1
12.1,3−ブチレングリコール 8.5
13.パラオキシ安息香酸エチル 0.05
14.パラオキシ安息香酸メチル 0.2
15.精製水 66.15
[製造方法]成分3〜10を加熱溶解して混合し、70℃に保ち油相とする。成分1及び2と成分12〜15を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分11を加え、更に30℃まで冷却して製品とする。
Formulation Example 2 Cream 2
Formulation Formulation 1. Roda hot water extract (Production Example 4) 1.0 part Hantai Kai hot water extract (Production Example 7) 1.0
3. Squalane 5.5
4). Olive oil 3.0
5). Stearic acid 2.0
6). Beeswax 2.0
7). Octyldodecyl myristate 3.5
8). Polyoxyethylene cetyl ether (20E.O.) 3.0
9. Behenyl alcohol 1.5
10. Glycerol monostearate2.5
11. Fragrance 0.1
12.1,3-Butylene glycol 8.5
13. Ethyl paraoxybenzoate 0.05
14 Methyl paraoxybenzoate 0.2
15. Purified water 66.15
[Manufacturing method] Components 3 to 10 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 2 and ingredients 12-15 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring.
処方例3 クリーム3
処方例1において、アサナの熱水抽出物を、サクナの50%1,3−ブチレングリコール水溶液抽出物(製造例12)に置き換えたものをクリーム3とした。
Formulation Example 3 Cream 3
In Formulation Example 1, Cream 3 was obtained by replacing the hot water extract of asana with a 50% 1,3-butylene glycol aqueous solution extract of Sacna (Production Example 12).
比較例1 従来のクリーム
処方例1において、アサナの熱水抽出物を精製水に置き換えたものを従来のクリームとした。
Comparative Example 1 Conventional Cream In Formulation Example 1, a hot cream extract of asana was replaced with purified water to obtain a conventional cream.
処方例4 化粧水
処方 配合量
1.ロッダのエタノール抽出物(製造例5) 0.1部
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 0.1
11.精製水 84.47
[製造方法]成分2〜6及び11と、成分1及び成分7〜10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Formulation Example 4 Lotion Formulation Formulation amount 1. Rhoda ethanol extract (Production Example 5) 0.1 part 2.1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5). Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Fragrance 0.1
11. Purified water 84.47
[Manufacturing method] Components 2-6 and 11 and components 1 and 7-10 are uniformly dissolved, mixed and filtered to obtain a product.
処方例5 乳液1
処方 配合量
1.アサナの50%1,3−ブチレングリコール水溶液抽出物(製造例3)0.5部
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート(20E.O.) 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水 72.7
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分1及び10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
Formulation Example 5 Latex 1
Formulation Formulation 1. 1. Asana 50% 1,3-butylene glycol aqueous solution extract (Production Example 3) 0.5 part Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5). Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. Purified water 72.7
[Manufacturing method] Components 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 9 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
処方例6 乳液2
処方例5において、アサナの50%1,3−ブチレングリコール水溶液抽出物0.5部をロッダの熱水抽出物(製造例4)0.25部とサクナの熱水抽出物(製造例10)0.25部に置き換えたものを乳液2とした。
Formulation Example 6 Latex 2
In Formulation Example 5, 0.5 part of 50% 1,3-butylene glycol aqueous extract of asana was mixed with 0.25 part of Rodda's hot water extract (Production Example 4) and hot water extract of Sacna (Production Example 10). The emulsion 2 was replaced with 0.25 part.
処方例7 ゲル剤
処方 配合量
1.ハンタイカイの50%1,3−ブチレングリコール水溶液抽出物
(製造例9) 1.0部
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5.香料 0.05
6.1,3−ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水 83.25
[製造方法]成分2〜5と、成分1及び6〜11をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation Example 7 Gel formulation Formulation amount 1. 50% 1,3-butylene glycol aqueous extract of hantaikai
(Production Example 9) 1.0 part Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
5). Fragrance 0.05
6.1,3-Butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. Purified water 83.25
[Manufacturing method] Components 2 to 5 and components 1 and 6 to 11 are uniformly dissolved and mixed to obtain a product.
処方例8 パック
処方 配合量
1.ハンタイカイのエタノール抽出物(製造例8) 0.1部
2.サクナの熱水抽出物(製造例10) 0.1
3.ポリビニルアルコール 12.0
4.エタノール 5.0
5.1,3−ブチレングリコール 8.0
6.パラオキシ安息香酸メチル 0.2
7.ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
8.クエン酸 0.1
9.クエン酸ナトリウム 0.3
10.香料 0.05
11.精製水 73.65
[製造方法]成分1〜11を均一に溶解し製品とする。
Formulation Example 8 Pack Formulation Formulation 1. Hantaikai ethanol extract (Production Example 8) 0.1 part Sacna hot water extract (Production Example 10) 0.1
3. Polyvinyl alcohol 12.0
4). Ethanol 5.0
5.1,3-butylene glycol 8.0
6). Methyl paraoxybenzoate 0.2
7). Polyoxyethylene hydrogenated castor oil (20 EO) 0.5
8). Citric acid 0.1
9. Sodium citrate 0.3
10. Fragrance 0.05
11. Purified water 73.65
[Production method] Components 1 to 11 are uniformly dissolved to obtain a product.
処方例9 ファンデーション
処方 配合量
1.アサナのエタノール抽出物(製造例2) 0.5部
2.サクナのエタノール抽出物(製造例11) 0.5
3.ステアリン酸 2.4
4.ポリオキシエチレンソルビタンモノステアレート(20E.O.) 1.0
5.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
6.セタノール 1.0
7.液状ラノリン 2.0
8.流動パラフィン 3.0
9.ミリスチン酸イソプロピル 6.5
10.カルボキシメチルセルロースナトリウム 0.1
11.ベントナイト 0.5
12.プロピレングリコール 4.0
13.トリエタノールアミン 1.1
14.パラオキシ安息香酸メチル 0.2
15.二酸化チタン 8.0
16.タルク 4.0
17.ベンガラ 1.0
18.黄酸化鉄 2.0
19.香料 0.1
20.精製水 60.1
[製造方法]成分1〜8を加熱溶解し、80℃に保ち油相とする。成分20に成分10をよく膨潤させ、続いて、成分12〜14を加えて均一に混合する。これに粉砕機で粉砕混合した成分15〜18を加え、ホモミキサーで撹拌し75℃に保ち水相とする。この水相に油相をかき混ぜながら加え、冷却し、45℃で成分19を加え、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 9 Foundation Formulation Formulation amount 1. Asana ethanol extract (Production Example 2) 0.5 part Sacuna ethanol extract (Production Example 11) 0.5
3. Stearic acid 2.4
4). Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
5). Polyoxyethylene cetyl ether (20E.O.) 2.0
6). Cetanol 1.0
7). Liquid lanolin 2.0
8). Liquid paraffin 3.0
9. Isopropyl myristate 6.5
10. Sodium carboxymethylcellulose 0.1
11. Bentonite 0.5
12 Propylene glycol 4.0
13. Triethanolamine 1.1
14 Methyl paraoxybenzoate 0.2
15. Titanium dioxide 8.0
16. Talc 4.0
17. Bengala 1.0
18. Yellow iron oxide 2.0
19. Fragrance 0.1
20. Purified water 60.1
[Production Method] Components 1 to 8 are heated and dissolved, and kept at 80 ° C. to obtain an oil phase. Swell component 10 well with component 20, then add components 12-14 and mix uniformly. To this, components 15 to 18 pulverized and mixed with a pulverizer are added, and the mixture is stirred with a homomixer and kept at 75 ° C. to obtain an aqueous phase. The oily phase is added to the aqueous phase with stirring, cooled, and component 19 is added at 45 ° C, and cooled to 30 ° C with stirring to give a product.
処方例10 軟膏
処方 配合量
1.アサナの熱水抽出物(製造例1) 0.01部
2.ロッダの50%1,3−ブチレングリコール抽出物(製造例6) 0.5
3.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
4.モノステアリン酸グリセリン 10.0
5.流動パラフィン 5.0
6.セタノール 6.0
7.パラオキシ安息香酸メチル 0.1
8.プロピレングリコール 10.0
9.精製水 66.39
[製造方法]成分3〜6を加熱溶解して混合し、70℃に保ち油相とする。成分1、2及び7〜9を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 10 Ointment Formulation Formulation amount 1. Asana hot water extract (Production Example 1) 0.01 part2. 50% 1,3-butylene glycol extract of Rodda (Production Example 6) 0.5
3. Polyoxyethylene cetyl ether (30E.O.) 2.0
4). Glycerol monostearate 10.0
5). Liquid paraffin 5.0
6). Cetanol 6.0
7). Methyl paraoxybenzoate 0.1
8). Propylene glycol 10.0
9. Purified water 66.39
[Production Method] Components 3 to 6 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1, 2 and 7-9 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.
処方例11 飲料
処方 配合量(重量%)
1.アサナの熱水抽出物(製造例1) 1.0
2.ステビア 0.05
3.リンゴ酸 5.0
4.香料 0.1
5.水 93.85
[製造方法]成分2及び3を少量の水に溶解する。次いで、成分1及び4、5を加えて混合する。
Formulation Example 11 Beverage Formulation Formulation amount (% by weight)
1. Asana hot water extract (Production Example 1) 1.0
2. Stevia 0.05
3. Malic acid 5.0
4). Fragrance 0.1
5). Water 93.85
[Production Method] Components 2 and 3 are dissolved in a small amount of water. Components 1 and 4, 5 are then added and mixed.
処方例12 錠剤
処方 配合量(重量%)
1.ハンタイカイの熱水抽出物(製造例7) 10.0
2.トウモロコシデンプン 10.0
3.精製白糖 20.0
4.カルボキシメチルセルロース 10.0
5.微結晶セルロース 35.0
6.ポリビニルピロリドン 5.0
7.タルク 10.0
[製造方法]成分1〜5を混合し、次いで成分6の水溶液を結合剤として加えて常法により顆粒化した。これに滑沢剤として成分7を加えて配合した後、1錠100mgの錠剤に打錠した。
Formulation Example 12 Tablet Formulation Formulation amount (% by weight)
1. Hantai Kai hot water extract (Production Example 7) 10.0
2. Corn starch 10.0
3. Purified white sugar 20.0
4). Carboxymethylcellulose 10.0
5). Microcrystalline cellulose 35.0
6). Polyvinylpyrrolidone 5.0
7). Talc 10.0
[Production Method] Components 1 to 5 were mixed, and then an aqueous solution of Component 6 was added as a binder and granulated by a conventional method. This was mixed with ingredient 7 as a lubricant, and then tableted into 100 mg tablets.
次に、本発明の効果を詳細に説明するため、実験例を挙げる。 Next, experimental examples will be given to explain the effects of the present invention in detail.
実験例1 セラミド合成促進試験
マウスケラチノサイト由来細胞株であるPam212細胞を6cmディッシュに1×105個播種し、4日間培養した。その後、試料を最終濃度が10μg/mLになるように添加し、さらに24時間培養を続けた。次に細胞をPBS(−)にて3回洗浄した後、ラバーポリスマンにて集め、凍結乾燥した。クロロホルム:メタノール(2:1)1mLにて細胞から脂質を抽出し、その中のセラミド量をKisicらの蛍光法(Kisic A. and Rapport M.M., Journal of Lipid Research, 15, 179−180 (1974))により測定した。すなわち、脂質を3N塩酸0.15mLにて100℃で2時間加水分解し、デシケーター中で乾燥、塩酸除去した後、酢酸エチル2mLと0.1M酢酸緩衝液(pH3.7)1.25mLを加え、よく撹拌した。次に、フルオレスカミン溶液(フルオレスカミン 7mg/25mL アセトン)0.25mLを加え、よく撹拌した後、遠心分離し、酢酸エチル層の蛍光強度をEx410nm、Em490nmにて測定した。セラミドの合成促進率は、コントロールのセラミド生成量に対する比で求めた。
Experimental Example 1 Ceramide Synthesis Promotion Test 1 × 10 5 Pam212 cells, a mouse keratinocyte-derived cell line, were seeded in a 6 cm dish and cultured for 4 days. Thereafter, the sample was added to a final concentration of 10 μg / mL, and the culture was further continued for 24 hours. Next, the cells were washed three times with PBS (−), collected by a rubber policeman, and lyophilized. Lipids were extracted from cells with 1 mL of chloroform: methanol (2: 1), and the amount of ceramide in the cells was determined by the fluorescence method of Kisic et al. (Kisic A. and Rapport MM, Journal of Lipid Research, 15, 179-180. (1974)). That is, the lipid was hydrolyzed with 0.15 mL of 3N hydrochloric acid at 100 ° C. for 2 hours, dried in a desiccator, removed with hydrochloric acid, and then added with 2 mL of ethyl acetate and 1.25 mL of 0.1 M acetate buffer (pH 3.7). Stir well. Next, 0.25 mL of a fluorescamine solution (fluorescamine 7 mg / 25 mL acetone) was added, stirred well, then centrifuged, and the fluorescence intensity of the ethyl acetate layer was measured at Ex 410 nm and Em 490 nm. The rate of ceramide synthesis acceleration was determined by the ratio to the amount of ceramide produced by the control.
これらの実験結果を表1に示した。その結果、アサナ、ロッダ、ハンタイカイ及びサクナの抽出物は、コントロールと比較して優れたセラミド合成促進効果を示した。 The results of these experiments are shown in Table 1. As a result, the extracts of asana, rodda, hantaikai and sacuna showed an excellent ceramide synthesis promoting effect as compared with the control.
アサナ、ロッダ、ハンタイカイ及びサクナの抽出物から選ばれる2種以上の混合物についても同様にセラミド合成促進試験を行ったところ、優れたセラミド合成促進効果を示した。 When two or more mixtures selected from asana, rhoda, hantaikai and sacuna extracts were similarly tested, the ceramide synthesis promotion test showed excellent ceramide synthesis promotion effects.
実験例2 使用試験1
アサナの熱水抽出物、ロッダの熱水抽出物、ハンタイカイとサクナの熱水抽出物の1:1混合物の1%水溶液を用いて、肌荒れ、乾燥肌に悩む女性30人(19才〜48才)を対象に1ヶ月間の使用試験を行った。使用後、肌荒れ、乾燥肌の改善作用をアンケートにより判定した。なお対照としては精製水を用いた。
Experiment 2 Use test 1
30 women (19 to 48 years old) suffering from rough skin and dry skin using 1% aqueous solution of hot water extract of asana, hot water extract of rodda, 1: 1 hot water extract of hantaikai and sakuna ) Was used for 1 month. After use, the improvement effect of rough skin and dry skin was determined by questionnaire. As a control, purified water was used.
これらの試験結果を表2に示した。その結果、アサナの熱水抽出物、ロッダの熱水抽出物、ハンタイカイとサクナの熱水抽出物1:1混合物の1%水溶液を用いた場合は、対照として精製水を用いた場合よりも、優れた肌荒れ、乾燥肌の改善効果を示した。すなわち、アサナの熱水抽出物、ロッダの熱水抽出物、ハンタイカイとサクナの熱水抽出物の1:1混合物の1%水溶液は顕著な効果を示した。なお、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。 The test results are shown in Table 2. As a result, when using 1% aqueous solution of hot water extract of asana, hot water extract of rodda, 1: 1 mixture of hot water extract of hantaikai and sakuna, compared to the case of using purified water as a control, Excellent skin roughness and dry skin improvement effect. That is, a 1% aqueous solution of a hot water extract of asana, a hot water extract of rodda, and a 1: 1 mixture of a hot water extract of hantaikai and sacuna showed remarkable effects. During the test period, there was no skin problem and there was no problem with safety.
アサナ、ロッダ、ハンタイカイ及びサクナの抽出物から選ばれる1種又は2種以上を含有するその他の水溶液についても同様に使用試験を行ったところ、安全であり、優れた肌荒れ、乾燥肌の改善効果を示した。 A similar test was conducted on other aqueous solutions containing one or more selected from the extracts of asana, rodda, hantaikai and sacuna. It was safe and had excellent effects on improving rough and dry skin. Indicated.
実験例3 使用試験2
処方例1〜3のクリーム、比較例1の従来のクリームを用いて、肌荒れ、乾燥肌に悩む女性30人(19〜49才)を対象に1ヶ月間の使用試験を行った。使用後、肌荒れ、乾燥肌の改善作用をアンケートにより判定した。
Experiment 3 Use test 2
Using the creams of Formulation Examples 1 to 3 and the conventional cream of Comparative Example 1, a one month use test was conducted on 30 women (19 to 49 years old) who suffer from rough skin and dry skin. After use, the improvement effect of rough skin and dry skin was determined by questionnaire.
これらの試験結果を表3に示した。その結果、処方例1〜3で得られるクリームは、比較例1で得られる従来のクリームよりも、肌荒れ、乾燥肌の予防改善効果に優れていた。なお、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。また、処方成分の劣化についても問題なかった。 The test results are shown in Table 3. As a result, the creams obtained in Formulation Examples 1 to 3 were superior to the conventional cream obtained in Comparative Example 1 in the effect of preventing and improving rough skin and dry skin. During the test period, there was no skin problem and there was no problem with safety. There was also no problem with the deterioration of the prescription ingredients.
処方例4〜10についても同様に使用試験を行ったところ、安全であり、優れた肌荒れ、乾燥肌の予防改善作用を示した。 When the usage test was similarly conducted for Formulation Examples 4 to 10, it was safe, and showed excellent rough skin prevention and dry skin prevention and improvement.
本発明のアサナ、ロッダ、ハンタイカイ及びサクナの抽出物から選ばれる1種又は2種以上は優れたセラミド合成促進剤として用いることが出来る。また、安全で肌荒れ、乾燥肌の改善効果に優れた皮膚外用剤を提供できる。
One or more selected from the extracts of asana, rodda, hantaikai and sacuna of the present invention can be used as an excellent ceramide synthesis accelerator. In addition, it is possible to provide an external preparation for skin that is safe, rough, and excellent in improving dry skin.
Claims (2)
A skin external preparation excellent in the effect of preventing or improving rough skin and dry skin, comprising the ceramide synthesis promoter according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004003287A JP4579550B2 (en) | 2004-01-08 | 2004-01-08 | Ceramide synthesis accelerator and external preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004003287A JP4579550B2 (en) | 2004-01-08 | 2004-01-08 | Ceramide synthesis accelerator and external preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005194239A true JP2005194239A (en) | 2005-07-21 |
JP4579550B2 JP4579550B2 (en) | 2010-11-10 |
Family
ID=34818247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004003287A Expired - Fee Related JP4579550B2 (en) | 2004-01-08 | 2004-01-08 | Ceramide synthesis accelerator and external preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4579550B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010024209A (en) * | 2008-07-24 | 2010-02-04 | Nippon Menaade Keshohin Kk | External preparation for skin |
JP2015209414A (en) * | 2014-04-30 | 2015-11-24 | 株式会社東洋新薬 | Oral composition |
US20150335692A1 (en) * | 2008-03-31 | 2015-11-26 | Shiseido Company, Ltd. | Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles |
KR101618309B1 (en) | 2015-05-20 | 2016-05-04 | 한국과학기술연구원 | Composition for anti-allergy and skin hydration comprising pterocarpus santalinus extracts |
KR20170032326A (en) | 2014-08-01 | 2017-03-22 | 가부시키가이샤 시세이도 | Longevity gene expression enhancer |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09255573A (en) * | 1996-03-28 | 1997-09-30 | Lion Corp | Composition for treating acne |
JP2000247829A (en) * | 1999-02-24 | 2000-09-12 | Mikimoto Pharmaceut Co Ltd | Cosmetic, unregulated drug, medicine and food |
JP2001081027A (en) * | 1999-09-09 | 2001-03-27 | Ichimaru Pharcos Co Ltd | Antibacterial-antiseptic agent |
JP2001192317A (en) * | 2000-01-06 | 2001-07-17 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
JP2002029985A (en) * | 2000-07-19 | 2002-01-29 | Pola Chem Ind Inc | Corium collagen fiber bundle-restructuring agent and composition containing the same |
JP2002080338A (en) * | 2000-06-20 | 2002-03-19 | Shiseido Co Ltd | Antiaging skin care preparation |
JP2003155246A (en) * | 2001-11-20 | 2003-05-27 | Fancl Corp | Abirritant composition |
-
2004
- 2004-01-08 JP JP2004003287A patent/JP4579550B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09255573A (en) * | 1996-03-28 | 1997-09-30 | Lion Corp | Composition for treating acne |
JP2000247829A (en) * | 1999-02-24 | 2000-09-12 | Mikimoto Pharmaceut Co Ltd | Cosmetic, unregulated drug, medicine and food |
JP2001081027A (en) * | 1999-09-09 | 2001-03-27 | Ichimaru Pharcos Co Ltd | Antibacterial-antiseptic agent |
JP2001192317A (en) * | 2000-01-06 | 2001-07-17 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
JP2002080338A (en) * | 2000-06-20 | 2002-03-19 | Shiseido Co Ltd | Antiaging skin care preparation |
JP2002029985A (en) * | 2000-07-19 | 2002-01-29 | Pola Chem Ind Inc | Corium collagen fiber bundle-restructuring agent and composition containing the same |
JP2003155246A (en) * | 2001-11-20 | 2003-05-27 | Fancl Corp | Abirritant composition |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150335692A1 (en) * | 2008-03-31 | 2015-11-26 | Shiseido Company, Ltd. | Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles |
JP2010024209A (en) * | 2008-07-24 | 2010-02-04 | Nippon Menaade Keshohin Kk | External preparation for skin |
JP2015209414A (en) * | 2014-04-30 | 2015-11-24 | 株式会社東洋新薬 | Oral composition |
KR20170032326A (en) | 2014-08-01 | 2017-03-22 | 가부시키가이샤 시세이도 | Longevity gene expression enhancer |
KR20220113554A (en) | 2014-08-01 | 2022-08-12 | 가부시키가이샤 시세이도 | Longevity gene expression enhancer |
KR101618309B1 (en) | 2015-05-20 | 2016-05-04 | 한국과학기술연구원 | Composition for anti-allergy and skin hydration comprising pterocarpus santalinus extracts |
Also Published As
Publication number | Publication date |
---|---|
JP4579550B2 (en) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006111560A (en) | Ceramide synthesis promoter | |
JP2006124350A (en) | Nmf production promoter | |
JP5616045B2 (en) | Ceramide production promoter and moisturizer | |
JP2009029734A (en) | External preparation for skin | |
KR101419588B1 (en) | Composition for Moisturizing Skin Comprising Ginseng Oil as Active Ingredient | |
JP4980035B2 (en) | External preparation for skin, whitening agent and composition for internal use | |
JP4824181B2 (en) | Topical skin preparation | |
JP4579550B2 (en) | Ceramide synthesis accelerator and external preparation for skin | |
JP2007045733A (en) | Hyaluronidase inhibitor | |
EP3636266A1 (en) | Agent for inhibiting skin trouble and composition for inhibiting skin trouble | |
JP2005023021A (en) | Elastase inhibitor | |
JP5649995B2 (en) | Ceramide production promoter | |
JP4421847B2 (en) | Lipolysis accelerator | |
JP6723979B2 (en) | Wrinkle improver | |
JP2016210703A (en) | Clock gene expression promoting composition | |
KR101273027B1 (en) | Composition for inhibiting sebum secretion and anti-obesity comprising kaempferol | |
JP2005139141A (en) | Collagen synthesis promoter and external preparation for the skin | |
JP5405782B2 (en) | Ceramide production promoter and moisturizer | |
JP5167042B2 (en) | Ceramide production promoter, moisturizer and external preparation for skin | |
JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
JP5690149B2 (en) | External preparation or internal preparation | |
JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
JP2005194240A (en) | Ceramide synthesis promotor and skin care preparation for external use | |
JP2017088538A (en) | Filaggrin production promoter | |
JP6646534B2 (en) | Basic fibroblast growth factor production promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100730 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100826 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4579550 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |